Amgen’s Uplizna shows potential efficacy in rare inflammatory diseases
Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...
GlobalData on MSN14d
Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
As the Horizon acquisition reaps its benefits, Amgen is now turning eyes to its obesity and diabetes portfolio.
FierceBiotech15d
Amgen ghosts lung disease program after missing all 14 endpoints
too When asked on an Oct. 30 earnings call Q&A how Amgen is restocking its rare disease pipeline after eliminations such as the IPF program, both CEO Bob Bradway and Chief Scientific Officer and R ...